Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Moderna Inc.
Sponsor

Moderna Inc.

United States 325 Binney Street, 02142-1038, United States

About the sponsor

Research activity includes propionic acidemia, isolated methylmalonic acidemia due to methylmalonyl-CoA mutase deficiency, methylmalonic acidemia, phenylketonuria, and glycogen storage disease type 1a, with a focus on inherited conditions affecting metabolic function.

  • Propionic acidemia
  • Isolated methylmalonic acidemia
  • Phenylketonuria
  • Glycogen storage disease type 1a

These studies reflect interest in disorders with early onset, recurrent metabolic decompensation, and long-term disease burden.

About Specializations

Moderna Inc. runs clinical trials in conditions such as COVID-19, Influenza, Propionic acidaemia, Methylmalonic acidaemia, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

13 clinical trials

COVID-19+1

Recruiting

Effectiveness of mCOMBRIAX vaccine compared with high‑dose influenza vaccine and mRNA‑1273 in adults ≥65 years for prevention of influenza and COVID‑19

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years · Healthy volunteers
  • Substances:B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type)
  • Sponsor:Gentofte Hospital

Propionic acidaemia

Recruiting

A study to evaluate the long-term safety and effectiveness of mRNA-3927 in patients with Propionic Acidemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Modified Messenger Ribonucleic Acid Encoding Human Propionyl-Coenzyme A Carboxylase Alpha And Beta Subunits Encapsulated Into Lipid Nanoparticles
  • Sponsor:Moderna Inc.

Non-small cell lung cancer metastatic

Recruiting

Evaluation of mRNA-4359 Monotherapy and Combined Pembrolizumab Therapy in Advanced Solid Tumors: A Phase 1/2 Clinical Trial

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Moderna Inc.

Methylmalonic acidaemia

Recruiting

Study on Long-Term Safety of mRNA-3705 for Patients with Methylmalonic Acidemia (MMA)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Dexamethasone
  • Sponsor:Moderna Inc.

Cytomegalovirus immunisation

Not recruiting

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Moderna Inc.

COVID-19

Not recruiting

A Study Testing mRNA-1273 Vaccine Safety and Effectiveness Against Severe COVID-19 in Adults Aged 50-64 Years Without Risk Factors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · Healthy volunteers
  • Substances:Elasomeran
  • Sponsor:Gentofte Hospital

Lower respiratory tract infection

Not recruiting

Study on the Safety and Immune Response of mRNA-1345 and mRNA-1365 for Infants with Acute Lower Respiratory Infection Aged 5 to 24 Months

Registered drug
Countries:LatviaLatvia
  • Participants:0–17 years · Healthy volunteers
  • Substances:MRNA-1345
  • Sponsor:Moderna Inc.

Study on the Safety and Immune Response of mRNA-1345 Vaccine for Respiratory Syncytial Virus in Pregnant Women and Their Infants

Not recruiting
Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:MRNA-1345
  • Sponsor:Moderna Inc.

Influenza

Not recruiting

Study of mRNA-1010 Influenza Vaccine Compared to Standard Flu Vaccine in Adults 50 Years and Older

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:CX-037231
  • Sponsor:Moderna Inc.

Glycogen storage disease type I

Not recruiting

Study on the Safety and Effects of mRNA-3745 for Patients with Glycogen Storage Disease Type 1a (GSD1a)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Codeine Phosphate
  • Sponsor:Moderna Inc.

Methylmalonic acidaemia

Not recruiting

Study on mRNA-3705 for Patients with Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Modified Mrna Encoding Human Methylmalonyl-Coenzyme A Mutase Containing A Polymorphism At Position 671
  • Sponsor:Moderna Inc.

Propionic acidaemia

Not recruiting

Study on the Safety and Effectiveness of mRNA-3927 for Patients with Propionic Acidemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Codeine Phosphate
  • Sponsor:Moderna Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.